Abstract:Beta-thalassemia (β-thalassemia) is an autosomal recessive disorder caused by point mutations, insertions, and deletions in the HBB gene cluster, resulting in the underproduction of β-globin chains. The most severe type may demonstrate complications including massive hepatosplenomegaly, bone deformities, and severe growth retardation in children. Treatments for β-thalassemia include blood transfusion, splenectomy, and allogeneic hematopoietic stem cell transplantation (HSCT). However, long-term blood transfusions require regular iron removal therapy. For allogeneic HSCT, human lymphocyte antigen (HLA)-matched donors are rarely available, and acute graft-versus-host disease (GVHD) may occur after the transplantation. Thus, these conventional treatments are facing significant challenges. In recent years, with the advent and advancement of CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) gene editing technology, precise genome editing has achieved encouraging successes in basic and clinical studies for treating various genetic disorders, including β-thalassemia. Target gene-edited autogeneic HSCT helps patients avoid graft rejection and GVHD, making it a promising curative therapy for transfusion-dependent β-thalassemia (TDT). In this review, we introduce the development and mechanisms of CRISPR/Cas9. Recent advances on feasible strategies of CRISPR/Cas9 targeting three globin genes (HBB, HBG, and HBA) and targeting cell selections for β-thalassemia therapy are highlighted. Current CRISPR-based clinical trials in the treatment of β-thalassemia are summarized, which are focused on γ-globin reactivation and fetal hemoglobin reproduction in hematopoietic stem cells. Lastly, the applications of other promising CRISPR-based technologies, such as base editing and prime editing, in treating β-thalassemia and the limitations of the CRISPR/Cas system in therapeutic applications are discussed.

Therapeutic Effects of Induced Pluripotent Stem Cells in Chimeric Mice with Β-Thalassemia.

Therapeutic Effects of Hematopoietic Stem Cell Derived From Gene-Edited Mice on β654-Thalassemia

A Novel Transgenic Mouse Model Produced from Lentiviral Germline Integration for the Study of Beta-Thalassemia Gene Therapy

Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice

A comparison of intrauterine hemopoietic cell transplantation and lentiviral gene transfer for the correction of severe β-thalassemia in a HbbTh3/+ murine model

Amelioration of Β654-Thalassemia in Mouse Model with the Knockdown of Aberrantly Spliced Β-Globin Mrna

Restoration of the Balanced Alpha/Beta-Globin Gene Expression in Beta(654)-Thalassemia Mice Using Combined Rnai and Antisense Rna Approach

In situ correction of various β-thalassemia mutations in human hematopoietic stem cells

Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology

Correction of RNA splicing defect in β654-thalassemia mice using CRISPR/Cas9 gene-editing technology.

Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells

Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements

Correction of Beta-Thalassemia IVS-II-654 Mutation in a Mouse Model Using Prime Editing

Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology

Superior long-term repopulating capacity of G-CSF+plerixafor-mobilized blood: implications for stem cell gene therapy by studies in the Hbb(th-3) mouse model

Correction of Β 654 -Thalassaemia Mice Using Direct Intravenous Injection of Sirna and Antisense RNA Vectors

A Transgenic Mouse Model for Dna/Rna Gene Therapy of Human Beta Thalassemia

Gene Editing of the Endogenous Cryptic 3' Splice Site Corrects the RNA Splicing Defect in the β654-Thalassemia Mouse Model

CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia

Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology

Treatment of β 654 -thalassaemia by TALENs in a mouse model.

Therapeutic Effects of Induced Pluripotent Stem Cells in Chimeric Mice with Β-Thalassemia.

Therapeutic Effects of Hematopoietic Stem Cell Derived From Gene-Edited Mice on β654-Thalassemia

A Novel Transgenic Mouse Model Produced from Lentiviral Germline Integration for the Study of Beta-Thalassemia Gene Therapy

Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice

A comparison of intrauterine hemopoietic cell transplantation and lentiviral gene transfer for the correction of severe β-thalassemia in a HbbTh3/+ murine model

Amelioration of Β654-Thalassemia in Mouse Model with the Knockdown of Aberrantly Spliced Β-Globin Mrna

Restoration of the Balanced Alpha/Beta-Globin Gene Expression in Beta(654)-Thalassemia Mice Using Combined Rnai and Antisense Rna Approach

In situ correction of various β-thalassemia mutations in human hematopoietic stem cells

Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology

Correction of RNA splicing defect in β654-thalassemia mice using CRISPR/Cas9 gene-editing technology.

Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells

Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements

Correction of Beta-Thalassemia IVS-II-654 Mutation in a Mouse Model Using Prime Editing

Correction of RNA splicing defect in β&lt;sup&gt;654&lt;/sup&gt;-thalassemia mice using CRISPR/Cas9 gene-editing technology

Superior long-term repopulating capacity of G-CSF+plerixafor-mobilized blood: implications for stem cell gene therapy by studies in the Hbb(th-3) mouse model

Correction of Β 654 -Thalassaemia Mice Using Direct Intravenous Injection of Sirna and Antisense RNA Vectors

A Transgenic Mouse Model for Dna/Rna Gene Therapy of Human Beta Thalassemia

Gene Editing of the Endogenous Cryptic 3' Splice Site Corrects the RNA Splicing Defect in the β654-Thalassemia Mouse Model

CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia

Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology

Treatment of β 654 -thalassaemia by TALENs in a mouse model.

Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology